SOX18 and neoplasm: These oncogenic features of SOX17 and SOX18 are supported by their significant co-expression with endothelial and inflammatory mediators such as VCAM1 and STAT3, both of which are known to drive tumor-associated angiogenesis, immune evasion, and metastatic potential.